Soligenix (SNGX) announced the formation of a European Medical Advisory Board to provide additional medical/clinical strategic guidance to the company as it advances its confirmatory Phase 3 multicenter, double-blind, placebo-controlled study evaluating the safety and efficacy of HyBryte in the treatment of cutaneous T-cell lymphoma patients with early-stage disease. This confirmatory, 18-week study is expected to enroll approximately 80 patients in the United States and Europe, and is targeted to begin patient enrollment by the end of 2024 with top-line results anticipated in the second half of 2026.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SNGX:
- Soligenix initiates Phase 2 clinical trial of SGX945 in Behcet’s Disease
- Soligenix reports Q3 EPS (78c) vs. ($2.56) last year
- Soligenix granted Hong Kong patent for production of synthetic hypericin
- Biotech Alert: Searches spiking for these stocks today
- Soligenix enters partnership with Sterling Pharma